Gastrointestinal stromal tumor: a clinical overview

  • Quek R
  • George S
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Gastrointestinal stromal tumor (GIST) is a disease that was poorly understood historically. In the last decade, it has undergone a major transformation, sparked by the landmark discovery of the central role of activating KIT mutations in its pathogenesis and recognition of KIT protein expression (CD 117) as a reliable diagnostic marker of disease. The introduction and subsequent US Food and Drug administration approval of imatinib mesylate in the treatment of metastatic or unresectable GIST in February 1, 2002 has thrust this hitherto little known disease into the center stage of oncology, and GIST has served as a model for rationally designed drug trials in the field of cancer therapeutics since.

Author-supplied keywords

  • *Gastrointestinal Stromal Tumors/genetics/patholog
  • Digestive System Surgical Procedures
  • Family Health
  • Humans
  • Piperazines
  • Protein Kinase Inhibitors/therapeutic use
  • Proto-Oncogene Proteins c-kit/analysis/genetics
  • Pyrimidines

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • R Quek

  • S George

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free